Summit Therapeutics SMMT 深 沪
等待开盘 10-02 09:30:00 美东时间
16.69
-0.220
-1.30%
华盛通- 最 高17.495
- 今 开16.82
- 成交量 790.08万股
- 最 低 16.59
- 昨 收 16.91
- 总市值 133.14亿
- 52周最高 29.23
- 市盈率 静 --
- 换手率 0.99%
- 52周最低 12.07
- 委 比 -81.02%
- 总股本 7.98亿
- 历史最高 36.91
- 量 比 0.71
- 振 幅 5.35%
- 历史最低 0.66
- 每 手 1
- 风险率 2.61%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Robinhood Traders Just Went on Their Biggest Buying Binge Ever
Robinhood Markets, Inc‘s (NASDAQ:HOOD) retail crowd is buying the dips at a record pace. According to the company’s EntryPoint newsletter, retail traders on the platform made their highest-ever five-day net purchases of individual stocks. The trend marks a turnaround from last Wednesday’s and Monday...
今天 01:43
Summit Therapeutics Stock Climbs Wednesday: What's Happening?
Shares of Summit Therapeutics Inc. (NASDAQ:SMMT) moved higher in Wednesday afternoon trading, extending gains from the previous session following a landmark $2 billion strategic equity investment from pharmaceutical titan AstraZeneca to accelerate the clinical development of ivonescimab. Here’s what...
10-01 04:16
野村：予康方生物目标价138.29港元以及“买入”评级
9月30日，野村发布研报称，予康方生物（09926.HK）目标价138.29港元以及“买入”评级。康方生物及其海外合作伙伴Summit Therapeutic...
09-30 15:08
美股大行评级 | 潜在涨幅11184.05%！如瑞迪博士获花旗上调目标价至1450美元，维持"买入"评级
今日重点评级关注：花旗：上调如瑞迪博士"买入"评级，目标价从1040美元升至1450美元；加拿大帝国商业银行：维持Inventiva"买入"评级，目标价从20美元升至21美元
09-30 08:33
Citigroup Maintains Buy on Summit Therapeutics, Raises Price Target to $43
Citigroup analyst Yigal Nochomovitz maintains Summit Therapeutics (NASDAQ:SMMT) with a Buy and raises the price target from $40 to $43.
09-30 01:52
AstraZeneca submits NDA for savolitinib + Tagrisso for NSCLC
AstraZeneca has submitted an NDA to the US FDA seeking approval of a combination regimen of savolitinib plus Tagrisso (osimertinib) as a second-line therapy for locally advanced or metastatic non-smal...
09-30 01:28
美股异动｜Summit Therapeutics大涨超23%，获阿斯利康20亿美元投资
Summit Therapeutics(SMMT.US)盘初大涨超23%，最高触及19.07美元。消息面上，阿斯利康同意向临床阶段肿瘤公司Summit The...
09-29 21:58
AstraZeneca Invests in Summit Therapeutics after Year of Speculation
AstraZeneca Plc (NYSE:AZN) on Tuesday agreed to invest $2 billion in newly issued equity in Summit Therapeutics Inc. (NASDAQ:SMMT) to accelerate the development of ivonescimab in combination with antibody-drug conjugates (ADCs) across tumor types. In July 2025, media reports circulated related to th...
09-29 21:12
盘前：纳指期货涨0.45% 聚焦特朗普午餐会
周二美国股市和美国国债走势缺乏明确方向，交易员在本周首份劳动力市场数据公布，以及一系列人工智能相关活动到来之前保持观望。油价则震荡波动。债券收益率维持在多年...
09-29 20:30
美股前瞻 | 医药巨头豪掷20亿美元入股抗癌药企SMMT！特朗普释放美伊谈判利好；贝壳盘前巨震10%！房贷贴息政策重磅落地
“医药巨头”豪掷20亿美元官宣入股！抗癌药企Summit盘前飙涨20%；特朗普释放美伊谈判利好，存储股集体反弹；贝壳股价巨震10%！房贷贴息政策重磅落地>>
09-29 20:06
